CABA Stock Analysis: Buy, Sell, or Hold?
CABA - Cabaletta Bio, Inc. Common Stock
$3.13
-0.06 (-1.88%)
▼
5d:
+13.82%
30d:
+15.07%
90d:
-15.18%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CABA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CABA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CABA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CABA is currently trading at $3.13, which is considered extended relative to its 30-day fair value range of $2.66 to $2.92.
Technical Outlook: Technically, CABA is in a downtrend. Immediate support is located at $2.64, while resistance sits at $3.34.
Market Sentiment: CABA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+323.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CABA is in a downtrend. Immediate support is located at $2.64, while resistance sits at $3.34.
Market Sentiment: CABA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.25 (+323.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.66 -
$2.92
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+7.2% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 323.3% below Wall St target ($13.25)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.66 -
$2.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.64
Resistance Level
$3.34
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.12
Wall Street Target
$13.25
(+323.3%)
Share & Embed Analysis
Last updated: August 23, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CABA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
